1: Zheng B, Zhao Q, Yang W, Feng P, Xin C, Ying Y, Yang B, Han B, Zhu J, Zhang M, Li G. Small-molecule antiviral treatments for COVID-19: A systematic review and network meta-analysis. Int J Antimicrob Agents. 2024 Mar;63(3):107096. doi: 10.1016/j.ijantimicag.2024.107096. Epub 2024 Jan 18. 120(30):e2221809120. doi: 10.1073/pnas.2221809120. Epub 2023 Jul 17. 3: Yang D, Ju M, Wang H, Jia Y, Wang X, Fang H, Fan J. Efficacy and safety of proxalutamide (GT0918) in severe or critically ill patients with COVID-19: study protocol for a prospective, open-label, single-arm, single-center exploratory trial. BMC Pharmacol Toxicol. 2023 Jun 15;24(1):38. doi: 10.1186/s40360-023-00678-7. 4: Cheema HA, Rehman AU, Elrashedy AA, Mohsin A, Shahid A, Ehsan M, Ayyan M, Ismail H, Almas T. Antiandrogens for the treatment of COVID-19 patients: A meta- analysis of randomized controlled trials. J Med Virol. 2023 Apr;95(4):e28740. doi: 10.1002/jmv.28740. 37(7):e24880. doi: 10.1002/jcla.24880. Epub 2023 Apr 23.
合成参考文献
参考文献:10.1016/j.ijpharm.2014.08.047 摘要:Yang M, He S, Fan Y, Wang Y, Ge Z, Shan L, Gong W, Huang X, Tong Y, Gao C. Microenvironmental pH-modified solid dispersions to enhance the dissolution and bioavailability of poorly water-soluble weakly basic GT0918, a developing anti-prostate cancer drug: Preparation, characterization and evaluation in vivo. International Journal of Pharmaceutics. 2014 Nov;475(1-2):97–109. doi: 10.1016/j.ijpharm.2014.08.047.